AstraZeneca, strong sterling drag FTSE 100 lower ahead of key central bank decisions

London's FTSE 100 index edged down 0.12%, primarily impacted by a 3.4% drop in AstraZeneca shares following its decision to pause a £200 million investment, and pressure on export-oriented firms from a strong sterling. Investors are keenly awaiting a week of central bank decisions, including from the Bank of England, which is expected to hold interest rates steady. In contrast, the domestically focused FTSE 250 rose 0.43%, driven by an 11.3% surge in AO World after announcing a share buyback and an improved profit forecast, while Sainsbury's gained 5% after terminating talks with JD.com.

Analysis

The UK equity market is exhibiting a clear divergence, with the large-cap FTSE 100 index declining 0.12% while the domestically-focused FTSE 250 gained 0.43%. The FTSE 100's weakness is attributable to two primary factors: a significant company-specific event and adverse macroeconomic currency movements. Heavyweight component AstraZeneca (AZN) fell 3.4% after pausing a £200 million investment in its Cambridge research centre, which dragged the entire pharma and biotech sector down by 2.6%. Concurrently, a strengthening sterling weighed on the index's export-oriented constituents. In contrast, the FTSE 250's outperformance was driven by positive corporate news, including an 11.3% surge in AO World following its announcement of a share buyback and an upgraded profit forecast, and a 5% rise in Sainsbury's shares to a four-year high after it terminated sale talks for its Argos unit with JD.com. Investor sentiment remains cautious as the market anticipates a series of pivotal central bank decisions, most notably from the Bank of England, which is expected to hold interest rates steady amid rising inflation but potentially slow its bond unwind program.

Key Decisions for Investors

• Consider the divergent performance between the internationally-exposed FTSE 100 and the domestic FTSE 250, as sterling strength and company-specific issues create headwinds for large-caps while positive corporate actions are rewarding mid-caps.
• Monitor the healthcare and biotech sector following AstraZeneca's paused investment, as this may signal broader concerns about the UK's business climate for the industry.
• Maintain a cautious posture ahead of multiple central bank policy announcements this week, as any deviation from the Bank of England's expected rate hold could introduce significant volatility.
• Evaluate UK holdings based on company-specific catalysts, such as the share buybacks and M&A developments that drove significant gains in AO World and Sainsbury, which are currently overriding broader market sentiment.